A phase III study to evaluate WT1 cancer vaccine for the treatment of patients with acute myeloid leukemia
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2018
At a glance
- Drugs Galinpepimut S (Primary)
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- 27 Feb 2018 According to a Sellas Life Sciences media release, Dr. Gert Ossenkoppele will co-lead this trial
- 03 Oct 2016 According to a Sellas Life Sciences media release, the company expects to initiate this trial in the first half of 2017.
- 14 Sep 2016 According to Sellas Life Sciences Group media release, this trial is expected to start in early 2017.